Price reduction dilemma for 'Forxiga' set for withdrawal
By Lee, Tak-Sun | translator Kim, Jung-Ju
24.04.02 06:34:08
가나다라
0
The company has requested for a renegotiation and is currently awaiting DREC’s opinion
Strategy to maintain drug prices in Korea to sell Forxiga in other countries that reference drug prices in Korea
'Forxiga tab (dapagliflozin, AstraZeneca),' a diabetes treatment that was announced to be withdrawn from the Korean market in the second quarter of this year, has failed to reach an agreement in the price-volume agreement (PVA).
Initial negotiations fell apart, so the company is likely to attempt renegotiation. The company hopes to maintain a high drug price before withdrawing Forxiga from the Korean market because other countries reference drug pricing in Korea.
According to the industry on the 1st, AstraZeneca Korea negotiated with the National Health Insurance Service (NHIS) for Forxiga’s price-volume agreement (PVA), but they failed to reach an agreement.
As a
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)